Voyager Therapeutics Inc.

6.45+0.4100+6.79%Vol 99.19K1Y Perf 104.78%
Dec 2nd, 2022 16:00 DELAYED
BID6.02 ASK6.68
Open5.90 Previous Close6.04
Pre-Market- After-Market6.13
 - -  -0.32 -4.96%
Target Price
6.00 
Analyst Rating
Moderate Buy 2.50
Potential %
-6.98 
Finscreener Ranking
★+     43.36
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★+     42.87
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★+     42.65
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
48.51 
Earnings Rating
Neutral
Market Cap249.02M 
Earnings Date
8th Nov 2022
Alpha0.01 Standard Deviation0.26
Beta1.06 

Today's Price Range

5.816.45

52W Range

2.5410.60

5 Year PE Ratio Range

-5.109.50

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
17.06%
1 Month
24.52%
3 Months
-2.57%
6 Months
-0.31%
1 Year
104.78%
3 Years
-54.96%
5 Years
-55.33%
10 Years
-

TickerPriceChg.Chg.%
VYGR6.450.41006.79
AAPL147.81-0.5000-0.34
GOOG100.83-0.4500-0.44
MSFT255.020.33000.13
XOM109.86-0.9400-0.85
WFC45.94-0.9300-1.98
JNJ178.880.14000.08
FB196.640.99000.51
GE86.881.62001.90
JPM135.16-1.0800-0.79
 
ProfitabilityValueIndustryS&P 500US Markets
-
-29.20
-19.50
-371.70
-24.21
RevenueValueIndustryS&P 500US Markets
70.53M
1.83
19.44
54.07
Earnings HistoryEstimateReportedSurprise %
Q03 2022-0.190.45336.84
Q02 2022-0.56-0.5010.71
Q01 2022-0.14-0.56-300.00
Q04 2021-0.360.15141.67
Q03 2021-0.75-0.6710.67
Q02 2021-0.75-0.80-6.67
Q01 2021-0.71-0.5818.31
Q04 2020-0.52-0.4317.31
Earnings Per EndEstimateRevision %Trend
12/2022 QR-0.67-55.81Negative
12/2022 FY-1.1333.53Positive
3/2023 QR-0.71-44.90Negative
12/2023 FY-1.83-26.21Negative
Next Report Date-
Estimated EPS Next Report-0.19
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume99.19K
Shares Outstanding38.61K
Shares Float27.09M
Trades Count1.34K
Dollar Volume618.07K
Avg. Volume103.12K
Avg. Weekly Volume71.09K
Avg. Monthly Volume105.05K
Avg. Quarterly Volume133.22K

Voyager Therapeutics Inc. (NASDAQ: VYGR) stock closed at 6.45 per share at the end of the most recent trading day (a 6.79% change compared to the prior day closing price) with a volume of 99.19K shares and market capitalization of 249.02M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 186 people. Voyager Therapeutics Inc. CEO is G. Andre Turenne.

The one-year performance of Voyager Therapeutics Inc. stock is 104.78%, while year-to-date (YTD) performance is 138.01%. VYGR stock has a five-year performance of -55.33%. Its 52-week range is between 2.54 and 10.6, which gives VYGR stock a 52-week price range ratio of 48.51%

Voyager Therapeutics Inc. currently has a PE ratio of -12.10, a price-to-book (PB) ratio of 2.69, a price-to-sale (PS) ratio of 3.05, a price to cashflow ratio of 19.50, a PEG ratio of 2.32, a ROA of -9.30%, a ROC of -14.45% and a ROE of -20.42%. The company’s profit margin is -24.21%, its EBITDA margin is -19.50%, and its revenue ttm is $70.53 Million , which makes it $1.83 revenue per share.

Of the last four earnings reports from Voyager Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.19 for the next earnings report. Voyager Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Voyager Therapeutics Inc. is Moderate Buy (2.5), with a target price of $6, which is -6.98% compared to the current price. The earnings rating for Voyager Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Voyager Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Voyager Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 24.57, ATR14 : 0.39, CCI20 : 209.52, Chaikin Money Flow : -0.04, MACD : 0.13, Money Flow Index : 79.34, ROC : 16.64, RSI : 67.96, STOCH (14,3) : 100.00, STOCH RSI : 1.00, UO : 60.34, Williams %R : 0.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Voyager Therapeutics Inc. in the last 12-months were: Glenn F. Pierce (Sold 9 512 shares of value $63 730 ), Julie Burek (Sold 7 127 shares of value $35 465 ), Michael J. Higgins (Sold 13 891 shares of value $93 070 ), Robert W. Hesslein (Sold 15 093 shares of value $89 566 ), Robin Swartz (Sold 5 940 shares of value $49 201 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (25.00 %)
1 (25.00 %)
2 (40.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (75.00 %)
3 (75.00 %)
3 (60.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.50
Moderate Buy
2.50
Moderate Buy
2.20

Voyager Therapeutics Inc.

Voyager Therapeutics Inc is functional in the United States biotechnology industry. Its focus lies in the research and development of gene therapies for the cure of severe diseases of the central nervous system such as the Parkinson's, Huntington's and Alzheimer's disease. The company has developed products such as VY-AADC01 for Advanced Parkinson's Disease, VY-HTT01 for Huntington's Disease. Voyager's sole source of revenue is generated through its collaboration with a company called Genzyme. Genzyme funds the collaboration for the multiple gene therapy programs, including programs for Parkinson's disease, Friedreich's ataxia, and Huntington's disease, as well as other CNS disorders.

CEO: G. Andre Turenne

Telephone: +1 857 259-5340

Address: 75 Sidney Street, Cambridge 02139, MA, US

Number of employees: 186

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

64%36%

Bearish Bullish

51%49%


News

Stocktwits